Literature DB >> 24912767

β-adrenoceptor blockers valuable but higher doses not necessary.

Simon B Dimmitt1, Hans G Stampfer, John B Warren.   

Abstract

β-adrenoceptor blockers have an important role in the treatment of heart disease and are useful as an adjunct in systemic hypertension. They are often prescribed at unnecessarily high doses, near the top of the dose-response curve. Higher doses are associated with more adverse events, have not been shown to improve clinical outcomes in cardiac failure and may worsen outcome in hypertension. β-adrenoceptor blockers can be very effective in lower doses, guided by close monitoring of heart rate and blood pressure and, when used in combination with low dose vasodilators and diuretics, give a better risk benefit profile.
© 2014 The British Pharmacological Society.

Entities:  

Keywords:  bradycardia; cardiac failure; dose; hypertension; β-adrenoceptor blockers

Mesh:

Substances:

Year:  2014        PMID: 24912767      PMCID: PMC4243882          DOI: 10.1111/bcp.12439

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

Review 1.  Actual causes of death in the United States, 2000.

Authors:  Ali H Mokdad; James S Marks; Donna F Stroup; Julie L Gerberding
Journal:  JAMA       Date:  2004-03-10       Impact factor: 56.272

2.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).

Authors:  Paul A James; Suzanne Oparil; Barry L Carter; William C Cushman; Cheryl Dennison-Himmelfarb; Joel Handler; Daniel T Lackland; Michael L LeFevre; Thomas D MacKenzie; Olugbenga Ogedegbe; Sidney C Smith; Laura P Svetkey; Sandra J Taler; Raymond R Townsend; Jackson T Wright; Andrew S Narva; Eduardo Ortiz
Journal:  JAMA       Date:  2014-02-05       Impact factor: 56.272

3.  Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

Authors:  M Packer; P A Poole-Wilson; P W Armstrong; J G Cleland; J D Horowitz; B M Massie; L Rydén; K Thygesen; B F Uretsky
Journal:  Circulation       Date:  1999-12-07       Impact factor: 29.690

4.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

Authors:  M R Bristow; E M Gilbert; W T Abraham; K F Adams; M B Fowler; R E Hershberger; S H Kubo; K A Narahara; H Ingersoll; S Krueger; S Young; N Shusterman
Journal:  Circulation       Date:  1996-12-01       Impact factor: 29.690

5.  Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II).

Authors:  T Simon; M Mary-Krause; C Funck-Brentano; Ph Lechat; P Jaillon
Journal:  Eur Heart J       Date:  2003-03       Impact factor: 29.983

6.  Beta-blocker versus diuretic for control of the blood pressure response to stress in hypertensive patients.

Authors:  S C Wu; M B Secchi; S Mancarella; L Bettazzi; M Civelli; A Cirò; L Oltrona; G Folli
Journal:  Eur Heart J       Date:  1986-10       Impact factor: 29.983

7.  Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials.

Authors:  Dennis T Ko; Patricia R Hebert; Christopher S Coffey; Jeptha P Curtis; JoAnne M Foody; Artyom Sedrakyan; Harlan M Krumholz
Journal:  Arch Intern Med       Date:  2004-07-12

8.  Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF).

Authors:  John Wikstrand; Ake Hjalmarson; Finn Waagstein; Björn Fagerberg; Sidney Goldstein; John Kjekshus; Hans Wedel
Journal:  J Am Coll Cardiol       Date:  2002-08-07       Impact factor: 24.094

9.  Beta-blockers prevent subacute recurrences of persistent atrial fibrillation only in patients with hypertension.

Authors:  Trudeke Van Noord; Robert G Tieleman; Hans A Bosker; Tsjerk Kingma; Dirk J Van Veldhuisen; Harry J G M Crijns; Isabelle C Van Gelder
Journal:  Europace       Date:  2004-07       Impact factor: 5.214

10.  Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials.

Authors:  M R Law; N J Wald; J K Morris; R E Jordan
Journal:  BMJ       Date:  2003-06-28
View more
  6 in total

Review 1.  Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50.

Authors:  Simon B Dimmitt; Hans G Stampfer; Jennifer H Martin; Robin E Ferner
Journal:  Br J Clin Pharmacol       Date:  2019-08-19       Impact factor: 4.335

Review 2.  Why maximum tolerated dose?

Authors:  Hans G Stampfer; Genevieve M Gabb; Simon B Dimmitt
Journal:  Br J Clin Pharmacol       Date:  2019-07-22       Impact factor: 4.335

3.  When less is more - efficacy with less toxicity at the ED50.

Authors:  Simon Dimmitt; Hans Stampfer; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2017-04-06       Impact factor: 4.335

4.  β-blockers and risk of all-cause mortality in patients with chronic heart failure and atrial fibrillation-a meta-analysis.

Authors:  Tianyu Xu; Yuli Huang; Haobin Zhou; Yujia Bai; Xingfu Huang; Yunzhao Hu; Dingli Xu; Yuhui Zhang; Jian Zhang
Journal:  BMC Cardiovasc Disord       Date:  2019-06-03       Impact factor: 2.298

5.  Predictors of short-term mortality after rheumatic heart valve surgery: A single-center retrospective study.

Authors:  Khalid S Ibrahim; Khalid A Kheirallah; Fadia A Mayyas; Nizar R Alwaqfi; Murtada H Alawami; Qusai M Aljarrah
Journal:  Ann Med Surg (Lond)       Date:  2021-01-26

6.  Effectiveness and Tolerability of Trimetazidine 80 Mg Once Daily in Patients with Stable Angina Uncontrolled with Bisoprolol-Based Therapy: The Modus Vivendi Observational Study.

Authors:  Yuri Lopatin; Parvoleta Petrova
Journal:  Cardiol Ther       Date:  2021-12-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.